

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-41. (Cancelled)

42. (Currently amended) A method for treating cancer characterized by overexpression of HER2 receptor in a human comprising administering to the human subcutaneously a therapeutically effective amount of a formulation comprising an antibody which binds to an extracellular domain of HER2 receptor in an amount ~~of~~ from about 50 to 400mg/mL.

43. (Cancelled)

44. (Previously presented) The method of claim 42 wherein the formulation has been prepared by reconstituting lyophilized antibody in a diluent.

45. (Cancelled)

46. (Previously presented) The method of claim 42 wherein the cancer is selected from the group consisting of breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon and bladder cancer.

47. (Currently amended) A method for treating a human comprising administering subcutaneously a therapeutically effective amount of a stable reconstituted formulation to the human in order to treat cancer characterized by overexpression of HER2 receptor in the human, wherein the reconstituted formulation comprises an antibody which binds to an extracellular domain of HER2 receptor in an amount ~~of~~ from about 50 to 400mg/mL and has been prepared by reconstituting a lyophilized mixture of the antibody and a lyoprotectant in a diluent, wherein the antibody concentration in the reconstituted formulation is about 2-40 times greater than the antibody concentration in the mixture before lyophilization.

48.-50. (Cancelled)

51. (Previously presented) The method of claim 42 wherein the cancer is breast cancer.
52. (Previously presented) The method of claim 47 wherein the cancer is breast cancer.
53. (New) The method of claim 42 wherein the amount of the antibody in the formulation is from 50mg/mL to about 400mg/mL.
54. (New) The method of claim 42 wherein the amount of the antibody in the formulation is from about 80mg/mL to about 400mg/mL.
55. (New) The method of claim 42 wherein the amount of the antibody in the formulation is from about 80mg/mL to about 300mg/mL.
56. (New) The method of claim 42 wherein the amount of the antibody in the formulation is from 80mg/mL to about 300mg/mL.
57. (New) The method of claim 42 wherein the antibody comprises a recombinant humanized anti-HER2 (rhuMAb HER2) antibody.
58. (New) A method for treating cancer characterized by overexpression of HER2 receptor in a human comprising administering to the human subcutaneously a therapeutically effective amount of a formulation comprising a recombinant humanized anti-HER2 (rhuMAb HER2) antibody which binds to an extracellular domain of the HER2 receptor in an amount from 50 mg/mL to about 400mg/mL.
59. (New) A method for treating cancer characterized by overexpression of HER2 receptor in a human comprising administering to the human subcutaneously a therapeutically effective amount of a formulation comprising a recombinant humanized anti-HER2 (rhuMAb HER2) antibody which binds to an extracellular domain of the HER2 receptor in an amount of from about 80 mg/mL to about 300mg/mL.